Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system. Blockade of ...

On the basis of pathogenesis, two types of endometrial cancer can be recognized. Type 1 endometrial carcinomas are relatively indolent tumors that develop after prolonged estrogen stimulation, on a ...

Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that ...

Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors. Background: Programmed death-1 (PD-1), a T-cell inhibitory receptor, may suppress antitumor immunity. MDX-1106, a ...

Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended dose of 3 mg/m2 twice daily. Common adverse effects included weight gain, ...